Evaluation of Immune Response Against the Strain of Neisseria Meningitidis B: 14, P1-7, 16 in Patients Having to be Vaccinated MenBVac® (Extension EFFIVAC) (Exten Effivac)

University Hospital, Rouen

Status: Completed

Conditions: Neisseria Meningitidis

Treatments: Biological: MenBvac

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT01621945

2011/198/HP

Details and patient eligibility

About

The main objective of the study is to estimate the proportion of children, born between the 06/04/2004 and the 17/004/2008, living around Neufchatel en Bray, vaccinated by MenBVac, with a serum bactericidal activity against B:14,P1-7,16 clone related to a protection (>= 4), before the fourth dose of MenBvac and after: 6 weeks and one year after the fourth dose.

Enrollment: 120 patients

Sex: All

Ages: 4 to 8 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• children born between 06/04/2004 and 17/04/2008, living in Neufchatel en Bray,and Having participated to the first study,
• children who Have to be Vaccinated MenBVac® for the four times,
• parental authority(ies)assent.

Exclusion criteria

• no parental authority(ies)assent,
• no blood sample,
• impossibility of fourth vaccination,
• children yet vaccinated or non eligible for vaccination.

Trial design

120 participants in 1 patient group

Bras A

Description:

children, born between the 06/04/2004 and the 17/04/2008, living around Neufchatel en Bray, before the fourth dose of MenBVac

Treatment:

Biological: MenBvac